Black Swan Biotech is advancing precision medicine through NeuroPMO™, our proprietary phosphorodiamidate morpholino oligomer (PMO) platform — a distinct class of antisense oligonucleotide engineered for the CNS. NeuroPMO™ is designed to reach deep into neural tissue and act on the key biological pathways driving neurodegenerative disease. BSB is developing a next-generation platform of PMOs for the CNS, with the goal of delivering best-in-class new treatments for people living with ALS.
We are developing precision PMO medicines for CNS diseases, starting with Motor Neurone Disease (MND) and a lead focus on Amyotrophic Lateral Sclerosis (ALS). Our mission is to deliver targeted treatments: the right treatment for every patient thereby transforming clinical outcomes and improving quality of life for people living with ALS, and beyond.
Every patient is biologically unique. Precision medicine harnesses molecular, genetic, and clinical data to uncover the biology of disease at an individual level. By identifying the biological signals that drive disease, our approach enables more accurate diagnosis, improves patient selection for clinical trials, and accelerates the development of targeted therapies built around specific disease mechanisms — not a “one-size-fits-all” approach.
One Treatment Fits All
And Precision Diagnosis
Problem: MND/ALS patients often have toxic clumps of a protein called SOD1 in their brain and spinal cord. These clumps damage nerve cells, causing cell death and drive the progression of MND/ALS.
Wide influence: TDP-43 is a protein that regulates the activity of many genes (over 6000), including its own. Proper control of TDP-43 is essential for healthy cell function.
Gene Regulation and Repair: The FUS protein plays a crucial role in regulating gene activity and repairing DNA, protecting nerve cells from damage.
Great science is built through collaboration. We partner with leading research institutions, healthcare organisations, and clinical experts throughout the world to translate multi-omics insights into precision PMO medicines for ALS and other CNS diseases.
Whether you're interested in research collaboration, strategic partnerships, investment opportunities, or learning more about our technology, we'd love to hear from you.
